Fibrin Sealant in Operative Medicine Volume 1: Otorhinolaryngology
- PDF / 25,440,330 Bytes
- 172 Pages / 481.92 x 691.68 pts Page_size
- 93 Downloads / 183 Views
Fibrin Sealant in Operative Medicine Volume 1
Otorhinolaryngology
Springer-Verlag Berlin Heidelberg New York London Paris Tokyo
Professor Dr. Gunther Schlag Dozent Dipl.-Ing. Dr. Heinz Redl Ludwig-Boltzmann-Institut fUr experimentelle Traumatologie DonaueschingenstraBe 13 A-1200 Vienna
Tissucol or Tisseel are registered trademarks of IMMUNO's two-component fibrin sealant in different countries
ISBN-13: 978-3-540-16734-1 e-ISBN-13: 978-3-642-71359-0 DOl: 10.1007/978-3-642-71359-0
This work is to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use, a fee is payable to "Verwertungsgesellschaft Wort," Munich. © by Springer-Verlag Berlin Heidelberg 1986 The use of general descriptive names, trade names, trade marks, etc. in this publication, even if the former are not especially identified, is not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.
2127/3140-543210
Preface
Fibrin plays a prominent role in wound healing. It has a hemostatic effect, induces cellular response to wound damage,' and, by forming strands to build a matrix, assists in neovascularization and fibroblast proliferation. The concept of using clotting substances from human blood for wound management and to achieve hemostasis in bleeding parenchymatous organs can be traced to 1909, when Bergel [1] reported on the hemostatic effect of fibrin powder. In 1915, Grey [3] employed fibrin to control bleeding in neurosurgical operations of the brain. A year later, Harvey [4] used fibrin patches to stop bleeding from parenchymatous organs in general surgery. It took more than two decades for this ingenious idea to be rediscovered. In 1940, Young and Medawar [8] reported on experimental nerve anastomosis by sealing. Similarly, Tarlov and Benjamin [7] reunited nerves with plasma clots in 1943. Tarlov improved the results obtained with clot anastomosing of nerves by avoiding tension at the nerve stumps. In 1944, Cronkite et al. [2] reported on an initial series of eight cases in which fibrinogen and thrombin had been used successfully for anchoring skin grafts. Although these early attempts suggested the basic advantages of using a biomaterial for wound closure - such as complete absorption, improved wound healing, and excellent tissue tolerance - the failure rate was relatively high, mainly because the fibrinogen employed had poor adhesive strength and the sealing did not last. It was because of these unsatisfactory results t
